medigraphic.com
ISSN 1817-5996 (Electronic)

2015, Number 3

<< Back Next >>

Rev Cub de Reu 2015; 17 (3)

Traditional risk factors and non traditional in a population of rheumatoid arthritis patients

Batún GJAJ, Hernández NÉ, Olán F

Language: Spanish
References: 30
Page: 200-207
PDF size: 145.58 Kb.


ABSTRACT

Introduction: patients with rheumatoid arthritis have twice the risk of cardiovascular diseases. This risk is not explained only by nontraditional factors, because these patients have associated factors with the disease itself which produce chronic inflammation.
Objective: determine the prevalence of traditional cardiovascular risk factors and non-traditional in a population of patients with rheumatoid arthritis.
Methods: a descriptive, cross-sectional, observational and prospective study was done in 126 patients diagnosed with rheumatoid arthritis according to ACR / EULAR 2010 criteria. Medical records were reviewed, excluding patients with previous cardiovascular disease. Traditional cardiovascular risk factors were recorded diabetes mellitus, hypertension, hypothyroidism, smoking, obesity, total cholesterol, HDL and LDL, triglycerides, and factors associated with rheumatoid arthritis, disease duration were recorded, DAS-28 C reactive protein, C reactive protein levels, use of glucocorticoids, rheumatoid factor positive, and positive antibody anti cyclic citrullinated peptide.
Results: 68 % of the population had hypertriglyceridemia, 60.3 % elevated LDL, 50 % hypercholesterolemia, 44.3 % hypoalphalipoproteinemia, 58.7 % presented obesity, 35.7 % had diabetes mellitus, 16.6 % hypertension , 7.1 % smoked and 3.1 % had hypothyroidism. Regarding the non-traditional risk factors 68.2 % had positive rheumatoid factor, 54.7 % were taking glucocorticoids, 25.4 % had C reactive protein › 2 mg / L, 20.6 % had more than 10 years of duration of the illness, the 7.9 % had positive antibody anti cyclic citrullinated peptide and 1.6 % had severe activity index. cardiovascular risk factors 10 years was calculated using the Framingham; 74.6 % showed slight risk, 24.6 % moderate and 0.8 % severe.
Conclusions: our rheumatoid arthritis patients had approximately two average nontraditional cardiovascular risk factors, which makes risk factors such as the Framingham not useful.


REFERENCES

  1. Méndez C, Andreu J, García B, Sangüesa C. Artritis reumatoide (II). Medicine. 2013;11(30):1850-5.

  2. Scott D, Wolfe F, Huizinga T. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-108.

  3. Symmons D, Gabriel S. Epidemiology of CVD in rheumatic disease, whit a focus on RA and SLE. Nat Rev Rheumtol. 2011;7:399-408.

  4. Hollan I, Meroni P, Ahearn J, Cohen J, Curran S, Goodyear C, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013;12:1004-15.

  5. Villa-Forte A, Mandell B. Cardiovascular disorders and rheumatic disease. Rev Esp Cardiol. 2011;64,809-17.

  6. Kitas G, Gabriel S. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70:8-14.

  7. Antohe J, Bili A, Sartorius J, Kirchner H, Morris S, Dancea S, et al. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy. Arthritis Care Res. 2012;64(2):215-21.

  8. Göran H. Inflammation, Atherosclerosis and Coronary Artery Disease. N Engl J Med. 2005;352:1685-95.

  9. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res. 2011;63:178-83.

  10. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-51.

  11. Gonzalez A, Maradit H, Crowson C, Ballman K, Roger V, Jacobsen S, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67:64-9.

  12. 1Skeoch S, Bruce I. Atherosclerosis in rheumatoid arthritis: is it all about inflammation?. Nat Rev Rheumatol. 2015;11:390-400.

  13. Panoulas V, Douglas K, Stavropoulos-Kalinoglou A, Metsios G, Nightingale P, Kita M, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology. 2008;47(1):72-5.

  14. Sihvonen S, Korpela M, Mustonen J, Huhtala H, Karstila K, Pasternack A. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol. 2006;33(9):1740-6.

  15. Book C, Saxne T, Jacobsson L. Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol. 2005;32(3):430-4.

  16. Banerjee S, Compton A, Hooker R, Cipher D, Reimold A, Brilakis E, et al. Cardiovascular outcomes in male

  17. veterans with rheumatoid arthritis. Am J Cardiol. 2008;101(8):1201-5.

  18. Marasovic D, Martinovic D, Fabijanic D, Morovic J. Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis?. Rheumatology. 2011;50(8):1505-12.

  19. Gonzalez-Gay M, Gonzalez-Juanatey C, Piñeiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol. 2005;32(7):1219-23.

  20. Danesh J, Wheeler J, Hirschfield G, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2008; 350: 1387-97.

  21. Myasoedova E, Gabriel S. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol. 2010; 22(3):342-7.

  22. Davis J, Maradit H, Crowson C, Nicola P, Ballman K, Therneau T, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;56 (3):820-30.

  23. Dessein P, Joffe B, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther. 2005;7(3):634-43.

  24. López-Longo FJ, Oliver-Miñarro D, de la Torre I, González-Díaz de Rábago E, Sánchez-Ramón S, Rodríguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(4):419-24.

  25. Hjeltnes G, Hollan I, Forre O, Wiik A, Mikkelsen K, Agewall S. Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients. Scand J Rheumatol. 2011;40(6):422-7.

  26. Kao A, Krishnaswami S, Cunningham A, Edmundowicz D, Morel P, Kuller L, et al. Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. J Rheumatol. 2008;35(1):61-9.

  27. Liang K, Myasoedova E, Crowson C, Davis J, Roger V, Karon B, et al. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis. 2010;69(9):1665-70.

  28. Nurmohamed M, Dijkmans B. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis. 2009;68:453-55.

  29. Ruiz-Esquide V, Sanmartí R. Tabaco y otros factores ambientales en la artritis reumatoide. Reumatol Clin. 2012;8(6):342-50

  30. Peters M, Symmons D, McCarey D, Dijkmans B, Nicola P, Kvien T, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-31.




2020     |     www.medigraphic.com